Navigation Links
Sanofi-Aventis renews licenses for Genomatix chip analysis pipeline

Genomatix Software GmbH (Munich) announced today that Sanofi-Aventis has renewed its licenses for Multi-Site access to the Genomatix Microarray Analysis Pipeline.

The pipeline provides a fully integrated, user friendly solution for the analysis of expression and tiling microarray experiments, including the powerful ChIP on chip studies. Genomatix software module ChipInspector seamlessly integrates with additional modules (BiblioSphere PathwayEdition, ElDorado, Gene2Promoter, and GEMS Launcher) to achieve a molecular level understanding of how genes are regulated and co-regulated, providing the scientists at Sanofi-Aventis a comprehensive gene network and pathway analysis.

Martin Seifert, Vice President Microarray Business and Collaborative Research at Genomatix stated: We are pleased that our existing relationship with Sanofi-Aventis has led to an extension of their existing licensing agreement. It confirms the validity of our integrated approach to understanding gene regulation by combining state of the art software, biological data bases, expert systems and scientific support, to provide a complete solution for the computational biologist.


Contact: Klaus May
Genomatix Software GmbH

Page: 1

Related medicine news :

1. FDA Gives Green Signal To Sanofi-Aventis SAs Cancer Drug Taxotere
2. Sanofi-Aventis sets the ball rolling for trials of H7N1 bird flu vaccine
3. Sanofi-Aventis Allows Thais To Make Plavix
4. U.N. Secretary-General Ban Renews Goal To Reverse Spread of HIV by 2015
5. US Government Licenses New Hypertension Drug
6. Panacea Biotec In-Licenses FMD Vaccine
7. Thailand Goes Ahead With Licenses for Generic Drugs
8. Swedish Biotech Licenses HIV Drug to China for Development
9. More Foreign Trained Doctors Receive Licenses
10. FDA Licenses First US Vaccine Against Avian Flu
11. Thailand Will Not Issue Compulsory Licenses for Patented Drugs
Post Your Comments:
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from reveals ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: